Cingulate reported on June 2 that the FDA issued a Complete Response Letter for CTx‑1301, its planned once‑daily, timed‑release dexmethylphenidate hydrochloride product for ADHD. The agency raised “specific Chemistry, Manufacturing, and Controls (CMC) information requests” after reviewing the company’s July 2025 submission, but did not question safety or efficacy. CEO Shane J. Schaffer said Cingulate is working with its manufacturing partner to complete the additional tasks and expects to resolve the FDA’s questions quickly. The Kansas City company holds around $30 million in cash to support the resubmission and related launch planning. Two more programs remain in development: CTx‑1302 for ADHD and CTx‑2103 for anxiety.
The rejection appears rooted in manufacturing process gaps, a logistical snag rather than a fundamental product issue. That distinction matters. Similar manufacturing snags have tripped up firms from AbbVie to Incyte in recent months. The signal to investors is clear: Cingulate’s science seems sound; the challenge lies in flawless execution. If the company completes the CMC work on schedule, it should still aim for an FDA resubmission during 2026, though the timeline depends on how long inspections and follow‑up data reviews take. And that’s anyone’s guess right now.
This episode also reflects how the FDA, post‑pandemic, leans harder on quality control for extended‑release formulations and third‑party manufacturing. For payers and PBMs, the delay means postponed competition in a long‑entrenched ADHD market dominated by legacy stimulants such as Focalin. Should Cingulate eventually prove that its platform sustains “all‑day efficacy” without mid‑day boosters, formulary behavior could shift toward single‑dose adherence strategies. A subtle shift, but one that payers will notice. For employer‑side PBM benchmarking, see RxPBM.ai.
